Literature DB >> 22610351

CD40 amplifies Fas-mediated apoptosis: a mechanism contributing to emphysema.

Ayako Shigeta1, Yuji Tada, Ji-Yang Wang, Shunsuke Ishizaki, Junichi Tsuyusaki, Keita Yamauchi, Yasunori Kasahara, Ken Iesato, Nobuhiro Tanabe, Yuichi Takiguchi, Akemi Sakamoto, Takeshi Tokuhisa, Kazutoshi Shibuya, Kenzo Hiroshima, James West, Koichiro Tatsumi.   

Abstract

Excessive apoptosis and prolonged inflammation of alveolar cells are associated with the pathogenesis of pulmonary emphysema. We aimed to determine whether CD40 affects alveolar epithelial cells and endothelial cells, with regard to evoking apoptosis and inflammation. Mice were repeatedly treated with agonistic-anti CD40 antibody (Ab), with or without agonistic-anti Fas Ab, and evaluated for apoptosis and inflammation in lungs. Human pulmonary microvascular endothelial cells and alveolar epithelial cells were treated with agonistic anti-CD40 Ab and/or anti-Fas Ab to see their direct effect on apoptosis and secretion of proinflammatory molecules in vitro. Furthermore, plasma soluble CD40 ligand (sCD40L) level was evaluated in patients with chronic obstructive pulmonary disease (COPD). In mice, inhaling agonistic anti-CD40 Ab induced moderate alveolar enlargement. CD40 stimulation, in combination with anti-Fas Ab, induced significant emphysematous changes and increased alveolar cell apoptosis. CD40 stimulation also enhanced IFN-γ-mediated emphysematous changes, not via apoptosis induction, but via inflammation with lymphocyte accumulation. In vitro, Fas-mediated apoptosis was enhanced by CD40 stimulation and IFN-γ in endothelial cells and by CD40 stimulation in epithelial cells. CD40 stimulation induced secretion of CCR5 ligands in endothelial cells, enhanced with IFN-γ. Plasma sCD40L levels were significantly increased in patients with COPD, inversely correlating to the percentage of forced expiratory volume in 1 s and positively correlating to low attenuation area score by CT scan, regardless of smoking history. Collectively CD40 plays a contributing role in the development of pulmonary emphysema by sensitizing Fas-mediated apoptosis in alveolar cells and increasing the secretion of proinflammatory chemokines.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22610351     DOI: 10.1152/ajplung.00337.2011

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  6 in total

1.  Lost in Trans-IL-6 Signaling: Alveolar Type II Cell Death in Emphysema.

Authors:  Irina Petrache; Karina Serban
Journal:  Am J Respir Crit Care Med       Date:  2016-12-15       Impact factor: 21.405

2.  OX62+OX6+OX35+ rat dendritic cells are unable to prime CD4+ T cells for an effective immune response following acute burn injury.

Authors:  Nadeem Fazal
Journal:  Results Immunol       Date:  2013-06-29

3.  Clinical, physiological, and radiological features of asthma-chronic obstructive pulmonary disease overlap syndrome.

Authors:  Toshio Suzuki; Yuji Tada; Naoko Kawata; Yukiko Matsuura; Jun Ikari; Yasunori Kasahara; Koichiro Tatsumi
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-05-15

4.  Preoperative soluble cluster of differentiation 40 ligand level is associated with outcome of pulmonary endarterectomy.

Authors:  Ayako Shigeta; Nobuhiro Tanabe; Akira Naito; Hajime Yokota; Fumiaki Kato; Takayuki Jujo-Sanada; Seiichiro Sakao; Keiichi Ishida; Masahisa Masuda; Koichiro Tatsumi
Journal:  JTCVS Open       Date:  2021-10-21

5.  Cigarette smoke exposure promotes differentiation of CD4+ T cells toward Th17 cells by CD40-CD40L costimulatory pathway in mice.

Authors:  Yi Liang; Ying Shen; Liangjian Kuang; Guang Zhou; Longju Zhang; Xiaoning Zhong; Jianquan Zhang; Jifeng Liu
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-03-21

Review 6.  Cigarette Smoke Particle-Induced Lung Injury and Iron Homeostasis.

Authors:  Andrew J Ghio; Elizabeth N Pavlisko; Victor L Roggli; Nevins W Todd; Rahul G Sangani
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-01-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.